Abstract
Nanoparticles (NPs) show great promise in the treatment of a wide range of diseases, which provides advantages and offers a new prospect for tumor detection, prevention and treatment. In order to eradicate the cancer cell, the NPs need to flow to different regions of tumors via blood vessels, and then penetrate through the interstitial space to reach the target cells. However, the environment and physiological characteristics in tumor tissues are different from that in normal ones, mainly in the irregular blood vessels, the lack of lymphatic network, low pH, hypoxia, immune function and so on. Meanwhile, the differences also exist among different tumor tissues. To achieve the optimal therapeutic effect, the NPs should be carefully designed by considering the therapeutic application, the target site and the route of administration. This review shows a variety of barriers in the tumor tissues, and provides a toolbox of designing the NPs for tumor treatment. In particular, the particle size, shape and surface chemistry, and the NPs in preclinical and clinical stage use have been discussed.
Keywords: Barriers, drug delivery, nanoparticles, size, shape, surface chemistry, tumor.
Mini-Reviews in Medicinal Chemistry
Title:The Toolbox of Designing Nanoparticles for Tumors
Volume: 14 Issue: 9
Author(s): Bochu Wang, Qian Yang, Yazhou Wang and Zong Li
Affiliation:
Keywords: Barriers, drug delivery, nanoparticles, size, shape, surface chemistry, tumor.
Abstract: Nanoparticles (NPs) show great promise in the treatment of a wide range of diseases, which provides advantages and offers a new prospect for tumor detection, prevention and treatment. In order to eradicate the cancer cell, the NPs need to flow to different regions of tumors via blood vessels, and then penetrate through the interstitial space to reach the target cells. However, the environment and physiological characteristics in tumor tissues are different from that in normal ones, mainly in the irregular blood vessels, the lack of lymphatic network, low pH, hypoxia, immune function and so on. Meanwhile, the differences also exist among different tumor tissues. To achieve the optimal therapeutic effect, the NPs should be carefully designed by considering the therapeutic application, the target site and the route of administration. This review shows a variety of barriers in the tumor tissues, and provides a toolbox of designing the NPs for tumor treatment. In particular, the particle size, shape and surface chemistry, and the NPs in preclinical and clinical stage use have been discussed.
Export Options
About this article
Cite this article as:
Wang Bochu, Yang Qian, Wang Yazhou and Li Zong, The Toolbox of Designing Nanoparticles for Tumors, Mini-Reviews in Medicinal Chemistry 2014; 14(9) . https://dx.doi.org/10.2174/1389557514666140820122307
DOI https://dx.doi.org/10.2174/1389557514666140820122307 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Improved Immunotoxins with Novel Functional Elements
Current Pharmaceutical Design DNA Methylation in Epithelial Ovarian Cancer: Current Data and Future Perspectives
Current Molecular Pharmacology Angiogenesis and Angiogenesis Inhibitors: a New Potential Anticancer Therapeutic Strategy
Current Drug Targets - Immune, Endocrine & Metabolic Disorders DNA Drug Design for Cancer Therapy
Current Pharmaceutical Design In vivo behavior and Safety of Lapatinib-Incorporated Lipid Nanoparticles
Current Pharmaceutical Biotechnology Immunotherapy of Cancer Based on DC-Tumor Fusion Vaccine
Current Immunology Reviews (Discontinued) A Review of Nanocarrier-Based CNS Delivery Systems
Current Drug Delivery Serum miRNAs Signature Plays an Important Role in Keloid Disease
Current Molecular Medicine Structure-Activity Relationship Analyses of Glycyrrhetinic Acid Derivatives as Anticancer Agents
Mini-Reviews in Medicinal Chemistry Gene Therapy Targeting in the Central Nervous System
Current Gene Therapy Histone Modifications as Molecular Targets in Nasopharyngeal Cancer
Current Medicinal Chemistry Anesthesia Issues in Central Nervous System Disorders
Current Aging Science On the Future Development of Optimally-Sized Lipid-Insoluble Systemic Therapies for CNS Solid Tumors and Other Neuropathologies
Recent Patents on CNS Drug Discovery (Discontinued) Evaluation of the in vivo Safety Profiles of Rictor Inhibition Using a Zebrafish Model
Current Pharmaceutical Design The Spleen Tyrosine Kinase (Syk) in Human Disease, Implications for Design of Tyrosine Kinase Inhibitor Based Therapy
Current Pharmaceutical Design Glioblastoma Stem-Like Cells – Isolation, Biology and Mechanisms of Chemotherapy Resistance
Current Signal Transduction Therapy Computational Analysis of miRNA and their Gene Targets Significantly Involved in Colorectal Cancer Progression
MicroRNA Rational Design of 5-Aminolevulinic Acid Derivatives Aimed at Improving Photodynamic Therapy
Current Medicinal Chemistry - Anti-Cancer Agents CEST MRI for Molecular Imaging of Brain Metabolites
Current Molecular Imaging (Discontinued) Novel Biomarkers of microRNAs in Gastric Cancer: An Overview from Diagnosis to Treatment
MicroRNA